{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T22:06:41Z","timestamp":1792274801118,"version":"4.4.0"},"reference-count":172,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,11]],"date-time":"2021-11-11T00:00:00Z","timestamp":1636588800000},"content-version":"vor","delay-in-days":41,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1007\/s13311-021-01108-4","type":"journal-article","created":{"date-parts":[[2021,11,11]],"date-time":"2021-11-11T17:09:41Z","timestamp":1636650581000},"page":"2397-2418","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":103,"title":["Update on Intravenous Immunoglobulin in Neurology: Modulating Neuro-autoimmunity, Evolving Factors on Efficacy and Dosing and Challenges on Stopping Chronic IVIg Therapy"],"prefix":"10.1016","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7070-1134","authenticated-orcid":false,"given":"Marinos C.","family":"Dalakas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1007\/s13311-021-01108-4_bib1","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1001\/jama.291.19.2367","article-title":"Intravenous immunoglobulin in autoimmune neuromuscular diseases","volume":"291","author":"Dalakas","year":"2004","journal-title":"JAMA"},{"key":"10.1007\/s13311-021-01108-4_bib2","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/nrneurol.2014.253","article-title":"Dalakas MC Intravenous immunoglobulin in neurology: mode of action and clinical efficacy","volume":"11","author":"Lunneman","year":"2015","journal-title":"Nat Rev Neurol"},{"key":"10.1007\/s13311-021-01108-4_bib3","doi-asserted-by":"crossref","unstructured":"Hughes RA, Dalakas MC, Cornblath DR et al Clinical applications of Intravenous immunoglobulin in neurology Clin Exp Immunol 158 Supp (1) 34\u201332, 2009","DOI":"10.1111\/j.1365-2249.2009.04025.x"},{"key":"10.1007\/s13311-021-01108-4_bib4","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJM199201093260206","article-title":"Manipulating the immune system with immune globulin","volume":"326","author":"Dwyer","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1007\/s13311-021-01108-4_bib5","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/j.1600-065X.1994.tb00858.x","article-title":"V region-mediated selection of autoreactive repertoires by intravenous immunoglobulin","volume":"139","author":"Kazatchkine","year":"1994","journal-title":"Immunol Rev"},{"key":"10.1007\/s13311-021-01108-4_bib6","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.pharmthera.2004.04.002","article-title":"The use of intravenous immunoglobulin in the treatment of autoimmune Neurological Disorders: Evidence-based indications and safety profile","volume":"102","author":"Dalakas","year":"2004","journal-title":"Pharmacol Therapeutics"},{"key":"10.1007\/s13311-021-01108-4_bib7","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1056\/NEJM199412153312409","article-title":"Transmission of viral infect ions through intravenous immune globulin","volume":"331","author":"Schiff","year":"1994","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1007\/s13311-021-01108-4_bib8","first-page":"1325","article-title":"Comparison of the efficacy of IGIV-C, 10% (caprylate\/chromatography) and IGIV-SD, 10% as replacement therapy in primary immune deficiency","volume":"3","author":"Roifman","year":"2003","journal-title":"A randomized double-blind trial. International Immunopharmacol"},{"key":"10.1007\/s13311-021-01108-4_bib9","doi-asserted-by":"crossref","unstructured":"Gelfand EW Intravenous immune globulin in autoimmune and inflammatory diseases. N Engl J Med2012Nov 22;367(21):2015-25. https:\/\/doi.org\/10.1056\/NEJMra1009433.","DOI":"10.1056\/NEJMra1009433"},{"key":"10.1007\/s13311-021-01108-4_bib10","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/0161-5890(88)90088-0","article-title":"Immunoglobulin G dimer: an idiotype\u2013anti-idiotype complex","volume":"25","author":"Tankersley","year":"1988","journal-title":"Mol Immunol"},{"key":"10.1007\/s13311-021-01108-4_bib11","doi-asserted-by":"crossref","unstructured":"Roux KH, Tankersley DL. A view of the human idiotypic repertoire. Electron microscopic and immunologic analyses of spontaneous idiotype\u2013anti-idiotype dimers in pooled human IgG. J Immunol 1990) 144, 1387\u201392","DOI":"10.4049\/jimmunol.144.4.1387"},{"key":"10.1007\/s13311-021-01108-4_bib12","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1172\/JCI114483","article-title":"Normal immunoglobulin G (IgG) for therapeutic use (intravenous Ig) contains anti-idiotypic specificities against an immunodominant, disease-associated, cross-reactive idiotype of human anti-thyroglobulin autoantibodies","volume":"85","author":"Dietrich","year":"1990","journal-title":"J Clin Invest"},{"key":"10.1007\/s13311-021-01108-4_bib13","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.1073\/pnas.89.8.3325","article-title":"Human autoantibodies reactive with synthetic autoantigens from T cell receptor V\u03b2 chain","volume":"89","author":"Marchalonis","year":"1992","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1007\/s13311-021-01108-4_bib14","doi-asserted-by":"crossref","unstructured":"Dalakas MC. (1995). Basic aspects of neuroimmunology as they relate to immunotherapeutic targets: present and future prospects. Ann Neurol 37, (S) 2\u201313.","DOI":"10.1002\/ana.410370703"},{"key":"10.1007\/s13311-021-01108-4_bib15","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1172\/JCI116240","article-title":"Intravenous immunoglobulin contains specific antibodies inhibitory of activation of T cells by staphylococcal toxin superantigens","volume":"91","author":"Takei","year":"1993","journal-title":"J Clin Invest"},{"key":"10.1007\/s13311-021-01108-4_bib16","article-title":"Dalakas MC Anti-neuronal antibodies within the IVIg preparations: Importance in clinical practice","author":"Dimitriadou","year":"2019","journal-title":"Neurotherapeutics"},{"key":"10.1007\/s13311-021-01108-4_bib17","doi-asserted-by":"crossref","unstructured":"Tsiortou P, Alexopoulos H, Dalakas MC GAD antibody-spectrum disorders: Progress in Clinical phenotypes, Immunopathogenesis and Therapeutic interventions Therapeutic Advances in Neurology 2021 Mar 30;14:17562864211003486.\u00a0https:\/\/doi.org\/10.1177\/17562864211003486. eCollection 2021.","DOI":"10.1177\/17562864211003486"},{"key":"10.1007\/s13311-021-01108-4_bib18","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1056\/NEJMra993360","article-title":"Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin","volume":"345","author":"Kazatchkine","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1007\/s13311-021-01108-4_bib19","doi-asserted-by":"crossref","unstructured":"Dalakas MC, Bitzogli\u00a0K, Alexopoulos H Anti-SARS-CoV-2 antibodies within IVIg preparations: Cross-reactivities with seasonal coronaviruses, natural autoimmunity and therapeutic implications Frontiers Immunol 2021 Feb 17;12:627285. eCollection 2021. https:\/\/doi.org\/10.3389\/fimmu.2021.627285.","DOI":"10.3389\/fimmu.2021.627285"},{"key":"10.1007\/s13311-021-01108-4_bib20","unstructured":"Le Bert N, Tan AT, Kunasegaran K et al SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls Nature https:\/\/doi.org\/10.1038\/s41586-020 2550-"},{"key":"10.1007\/s13311-021-01108-4_bib21","doi-asserted-by":"crossref","unstructured":"Lee PY Day-Lewis\u00a0M, Henderson\u00a0LA ,\u00a0et al Distinct clinical and immunological features of SARS-COV-2-induced multisystem inflammatory syndrome in children JCI 2020 Jul 23;141113. https:\/\/doi.org\/10.1172\/JCI141113","DOI":"10.1172\/JCI141113"},{"key":"10.1007\/s13311-021-01108-4_bib22","doi-asserted-by":"crossref","unstructured":"Gherebaghi N, Nejadrahim R, Mousavi SJ, Sadat-Ebrahimi SR, Hajizadeh R. The use of intravenous immunoglobulin gamma for the treatment of severe coronavirus disease 2019: a randomized placebo-controlled double-blind clinical trial BMC Infectious Diseases 2020, 20, 786","DOI":"10.1186\/s12879-020-05507-4"},{"key":"10.1007\/s13311-021-01108-4_bib23","doi-asserted-by":"crossref","first-page":"721","DOI":"10.7326\/0003-4819-126-9-199705010-00008","article-title":"Intravenous immunoglobulin therapy for neurological diseases","volume":"126","author":"Dalakas","year":"1997","journal-title":"Ann Intern Med"},{"key":"10.1007\/s13311-021-01108-4_bib24","doi-asserted-by":"crossref","first-page":"259","DOI":"10.7326\/0003-4819-121-4-199408150-00004","article-title":"Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: frequency and risk factors","volume":"121","author":"Sekul","year":"1994","journal-title":"Ann Intern Med"},{"issue":"Suppl 6","key":"10.1007\/s13311-021-01108-4_bib25","first-page":"S13","article-title":"Mechanisms of action of IVIg and therapeutic considerations in the treatment of acute and chronic demyelinating neuropathies","volume":"59","author":"Dalakas","year":"2002","journal-title":"Neurology"},{"key":"10.1007\/s13311-021-01108-4_bib26","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1172\/JCI118488","article-title":"Kazatchkine MD Antibodies to a conserved region of HLA class I molecules, capable of modulating CD8 T cell-mediated function, are present in pooled normal immunoglobulin for therapeutic use","volume":"97","author":"Kaveri","year":"1996","journal-title":"J Clin Invest."},{"key":"10.1007\/s13311-021-01108-4_bib27","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1002\/ana.410390121","article-title":"Intravenous y-globulin inhibits binding of anti-GMI to its target antigen","volume":"39","author":"Malik","year":"1996","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-021-01108-4_bib28","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1002\/ana.10205","article-title":"Intravenous immunoglobulins neutralize blocking antibodies in Guillain-Barr\u00e9 syndrome","volume":"51","author":"Buchwald","year":"2002","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-021-01108-4_bib29","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1002\/ana.10259","article-title":"Blockade of blocking antibodies in Guillain-Barr\u00e9 syndromes: \u201cunblocking\u201d the mystery of action of intravenous immunoglobulin","volume":"51","author":"Dalakas","year":"2002","journal-title":"Ann Neurol"},{"issue":"127","key":"10.1007\/s13311-021-01108-4_bib30","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1093\/brain\/awh127","article-title":"Anti-ganglioside antibody-mediated neuronal cytotoxicity and its protection by intravenous immunoglobulin: implications for immune neuropathies","volume":"2004","author":"Zhang","year":"2004","journal-title":"Brain"},{"key":"10.1007\/s13311-021-01108-4_bib31","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1002\/(SICI)1097-4598(199911)22:11<1479::AID-MUS3>3.0.CO;2-B","article-title":"Intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: present status and practical therapeutic guidelines","volume":"22","author":"Dalakas","year":"1999","journal-title":"Muscle Nerve"},{"key":"10.1007\/s13311-021-01108-4_bib32","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1002\/ana.410380214","article-title":"Acute axonal Guillain Barr\u00e9 syndrome with IgG antibodies against motor axons following parenteral injection of gangliosides","volume":"38","author":"Illa","year":"1995","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-021-01108-4_bib33","doi-asserted-by":"crossref","first-page":"11409","DOI":"10.1016\/S0021-9258(19)78139-3","article-title":"Cross linking of Fc receptor to surface immunoglobulin on B cells provides on inhibitory signal that closes the plasma membrane calcium channel","volume":"269","author":"Diegel","year":"1994","journal-title":"J Biol Chem"},{"key":"10.1007\/s13311-021-01108-4_bib34","doi-asserted-by":"crossref","first-page":"3124","DOI":"10.4049\/jimmunol.137.10.3124","article-title":"Cooperativity between B lymphocytes membrane molecules: independent ligand occupancy and crosslinking of antigen receptors and Fc gamma receptors downregulates B lymphocyte function","volume":"137","author":"Uher","year":"1986","journal-title":"J Immunol"},{"key":"10.1007\/s13311-021-01108-4_bib35","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1365-2249.1993.tb03407.x","article-title":"Antibodies to the CD5 molecule in Normal Human immunoglobulins for therapeutic use (intravenous immunoglobulins, IVIg)","volume":"92","author":"Vassilev","year":"1993","journal-title":"Clin Exp Immunol"},{"key":"10.1007\/s13311-021-01108-4_bib36","first-page":"187","volume":"176","author":"Zhu K-Y,Teferman T Maiti PK,","year":"2006","journal-title":"Intravenous Immunoglobulin suppresses experimental myasthenia gravis: Immunological mechanism I Neuroimmunol"},{"key":"10.1007\/s13311-021-01108-4_bib37","doi-asserted-by":"crossref","unstructured":"Dalakas MC Spaeth PJ The importance of FcRn in Neuro-immunotherapies: From IgG catabolism, FCGRT gene polymorphisms, IVIg dosing and efficiency to specific FcRn inhibitors Therapeutic Advances in Neurology2021 Feb 26;14:1756286421997381 eCollection 2021.\u00a0https:\/\/doi.org\/10.1177\/1756286421997381","DOI":"10.1177\/1756286421997381"},{"key":"10.1007\/s13311-021-01108-4_bib38","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1056\/NEJM199901213400311","article-title":"Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases","volume":"340","author":"Yu","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1007\/s13311-021-01108-4_bib39","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1055\/s-0037-1613331","article-title":"Intravenous immunoglobulin mediates an increase in ant-platelet antibody clearance via the FcRn receptor","volume":"88","author":"Hansen","year":"2002","journal-title":"Thromb Haemost"},{"key":"10.1007\/s13311-021-01108-4_bib40","doi-asserted-by":"crossref","first-page":"3440","DOI":"10.1172\/JCI24394","article-title":"Complete FcRn dependence for intravenous Ig therapy in autoimmune skin blistering diseases","volume":"115","author":"Li","year":"2005","journal-title":"J Clin Invest."},{"key":"10.1007\/s13311-021-01108-4_bib41","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1056\/NEJMoa01167","article-title":"High-dose intravenous immunoglobulin for Stiff-Person Syndrome","volume":"345","author":"Dalakas","year":"2001","journal-title":"N Engl J of Med"},{"key":"10.1007\/s13311-021-01108-4_bib42","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1212\/WNL.47.3.678","article-title":"Effects of intravenous immunoglobulin on muscle weakness and calcium-channel autoantibodies in the Lambert-Eaton myasthenic syndrome","volume":"47","author":"Bain","year":"1996","journal-title":"Neurology"},{"key":"10.1007\/s13311-021-01108-4_bib43","doi-asserted-by":"crossref","unstructured":"Su S et al VNTR2\/VNTR3 genotype in the FCGRT gene associates with the reduced effectiveness of intravenous immunoglobulin treatment in patients with myasthenia gravis Therapeutic Advances in Neurological Disorders 2021","DOI":"10.1177\/1756286420986747"},{"key":"10.1007\/s13311-021-01108-4_bib44","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1172\/JCI114387","article-title":"Mechanisms of therapeutic effect of high-dose intravenous immunoglobulin","volume":"84","author":"Basta","year":"1989","journal-title":"J Clin Invest"},{"key":"10.1007\/s13311-021-01108-4_bib45","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(03)14368-1","article-title":"Polymyositis and dermatomyositis","volume":"362","author":"Dalakas","year":"2003","journal-title":"Lancet"},{"key":"10.1007\/s13311-021-01108-4_bib46","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJM199312303292704","article-title":"A controlled trial of high-dose intravenous immunoglobulin infusions as treatment for dermatomyositis","volume":"329","author":"Dalakas","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1007\/s13311-021-01108-4_bib47","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1172\/JCI117520","article-title":"High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments","volume":"94","author":"Basta","year":"1994","journal-title":"J Clin Invest"},{"key":"10.1007\/s13311-021-01108-4_bib48","unstructured":"Dalakas MC Alexopoulos H, Spaeth PJ Complement in neurological disorders and emerging complement-targeted therapeutics Nature Rev Neurol 2020 10.1038s41582\u2013020\u20130400\u20130"},{"key":"10.1007\/s13311-021-01108-4_bib49","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S0165-5728(96)00133-6","article-title":"Increased in vitro uptake of the complement C3b in the serum of patients with Guillain Barre' syndrome, myasthenia gravis and dermatomyositis","volume":"71","author":"Basta","year":"1996","journal-title":"J Neuroimmunol"},{"key":"10.1007\/s13311-021-01108-4_bib50","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jneuroim.2019.02.001","article-title":"IVIg efficacy in CIDP patients is not associated with terminal complement inhibition","volume":"330","author":"Keller","year":"2019","journal-title":"J Neuroimmunol"},{"key":"10.1007\/s13311-021-01108-4_bib51","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1126\/science.291.5503.484","article-title":"Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor","volume":"291","author":"Samuelsson","year":"2001","journal-title":"Science"},{"key":"10.1007\/s13311-021-01108-4_bib52","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0165-5728(02)00430-7","article-title":"Intravenous immunoglobulin modulates lymphocyte CD54 and monocyte FCgammaRII expression in patients with chronic inflammatory neuropathies","volume":"135","author":"Creange","year":"2003","journal-title":"J Neuroimmunol"},{"key":"10.1007\/s13311-021-01108-4_bib53","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1006\/clim.1999.4823","article-title":"Downregulation of TGF-\u03b21 mRNA and protein in the muscles of patients with inflammatory myopathies after treatment with high-dose intravenous immunoglobulin","volume":"94","author":"Amemiya","year":"2000","journal-title":"Clin Immunol"},{"key":"10.1007\/s13311-021-01108-4_bib54","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1172\/JCI116862","article-title":"Binding of cytokines to pharmaceutically prepared human immunoglobulin","volume":"92","author":"Svenson","year":"1993","journal-title":"J Clin Invest"},{"key":"10.1007\/s13311-021-01108-4_bib55","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1006\/clin.1994.1091","article-title":"Effect of IVIg in peripheral blood B, NK, and T cell subpopulations in women with recurrent spontaneous abortions: specific effect on LFA-1 and CD56 molecules","volume":"71","author":"Rigal","year":"1994","journal-title":"Clin Immunol Immunopathol"},{"key":"10.1007\/s13311-021-01108-4_bib56","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1046\/j.1365-2249.1999.00757.x","article-title":"Administration of intravenous immunoglobulin (IVIg) in vivo downregulatory effects on the IL-1 system","volume":"115","author":"Ankrust","year":"1999","journal-title":"Clin Exp Immunol"},{"key":"10.1007\/s13311-021-01108-4_bib57","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1212\/WNL.54.1.65","article-title":"Dalakas MC Expression of matrix metalloproteinases in the muscles of patients with inflammatory Myopathies","volume":"54","author":"Choi","year":"2000","journal-title":"Neurology"},{"issue":"43","key":"10.1007\/s13311-021-01108-4_bib58","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/ana.410430404","article-title":"MMP-9 and MMP-7 are expressed in experimental autoimmune neuritis and the Guillain-Barre syndrome","volume":"1998","author":"Kieseier","year":"1998","journal-title":"Ann Neurol."},{"key":"10.1007\/s13311-021-01108-4_bib59","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1212\/WNL.52.9.1833","article-title":"I.V. immunoglobulin reduces circulating proinflammatory cytokines in Guillain-Barre syndrome","volume":"52","author":"Sharief","year":"1999","journal-title":"Neurology"},{"key":"10.1007\/s13311-021-01108-4_bib60","doi-asserted-by":"crossref","unstructured":"Dalakas MC. Basic aspects of neuroimmunology as they relate to immunotherapeutic targets: present and future prospects. Ann Neurol 1995; 37, (S) 2\u201313.","DOI":"10.1002\/ana.410370703"},{"key":"10.1007\/s13311-021-01108-4_bib61","doi-asserted-by":"crossref","first-page":"4788","DOI":"10.1073\/pnas.0807319106","article-title":"Impaired inhibitory Fcgamma receptor IIB expression on B cells in chronic inflammatory demyelinating polyneuropathy","volume":"106","author":"Tackenberg","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1007\/s13311-021-01108-4_bib62","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1126\/science.1154315","article-title":"Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc","volume":"320","author":"Anthony","year":"2008","journal-title":"Science"},{"key":"10.1007\/s13311-021-01108-4_bib63","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S1074-7613(03)00080-3","article-title":"Colony-stimulating factor-1-dependent macrophages are responsible for IVIG protection in antibody-induced autoimmune disease","volume":"18","author":"Bruhns","year":"2003","journal-title":"Immunity"},{"key":"10.1007\/s13311-021-01108-4_bib64","doi-asserted-by":"crossref","unstructured":"Nimmerjahn F, Ravetch JV. The antiinflammatory activity of IgG: the intravenous IgG paradox. J Exp Med. 2007 Jan 22;204(1):11-5. https:\/\/doi.org\/10.1084\/jem.20061788.","DOI":"10.1084\/jem.20061788"},{"key":"10.1007\/s13311-021-01108-4_bib65","doi-asserted-by":"crossref","first-page":"19571","DOI":"10.1073\/pnas.0810163105","article-title":"Identification of a receptor required for the anti-inflammatory activity of IVIG","volume":"105","author":"Anthony","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1007\/s13311-021-01108-4_bib66","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s13311-015-0391-5","article-title":"Dalakas MC Efficacy of Intravenous immunoglobulin in Neurological Diseases","volume":"13","author":"Lunneman","year":"2016","journal-title":"Neurotherapeutics"},{"key":"10.1007\/s13311-021-01108-4_bib67","doi-asserted-by":"crossref","unstructured":"Quast I, Keller CW, Maurer MA et al Sialylation of IgG Fc domain impairs complement dependent cytotoxicity. J Clin Invest 2015","DOI":"10.1172\/JCI82695"},{"key":"10.1007\/s13311-021-01108-4_bib68","unstructured":"Kuitwaard K van Doorn P A, Bengrine T et al Genetic biomarkers for intravenous immunoglobulin response in chronic inflammatory demyelinating polyradiculoneuropathy Eur J Neurol. 2021;00:1\u20137."},{"key":"10.1007\/s13311-021-01108-4_bib69","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/0140-6736(93)90563-V","article-title":"Soluble CD4, CD8 and HLA molecules in commercial immunoglobulin preparations","volume":"341","author":"Blasczyk","year":"1993","journal-title":"Lancet"},{"key":"10.1007\/s13311-021-01108-4_bib70","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1182\/blood-2002-05-1447","article-title":"Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin","volume":"101","author":"Bayry","year":"2003","journal-title":"Blood"},{"key":"10.1007\/s13311-021-01108-4_bib71","doi-asserted-by":"crossref","first-page":"3497","DOI":"10.1002\/art.11346","article-title":"Intravenous immunoglobulin abrogates dendritic cell differentiation induced by interferon-\u03b1 present in serum from patients with systemic lupus erythematosus","volume":"48","author":"Bayry","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1007\/s13311-021-01108-4_bib72","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1002\/(SICI)1097-4598(199709)20:9<1102::AID-MUS2>3.0.CO;2-C","article-title":"Effect of high-dose intravenous immunoglobulin on serum chemistry, hematology and lymphocyte subpopulations: assessments based on controlled treatment trials in patients with neurological diseases","volume":"20","author":"Koffman","year":"1997","journal-title":"Muscle Nerve"},{"key":"10.1007\/s13311-021-01108-4_bib73","doi-asserted-by":"crossref","first-page":"3781","DOI":"10.4049\/jimmunol.161.7.3781","article-title":"Therapeutic preparations of normal polyspecific IgG (IVIg) induce apoptosis in human lymphocytes and monocytes: a novel mechanism of action of IVIg involving the Fas apoptotic pathway","volume":"161","author":"Prasad","year":"1998","journal-title":"J Immunol"},{"key":"10.1007\/s13311-021-01108-4_bib74","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1126\/science.282.5388.490","article-title":"Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin","volume":"282","author":"Viard","year":"1998","journal-title":"Science"},{"key":"10.1007\/s13311-021-01108-4_bib75","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1093\/brain\/120.9.1533","article-title":"Human immunoglobulin ameliorates rat experimental allergic neuritis","volume":"120","author":"Gabriel","year":"1997","journal-title":"Brain"},{"key":"10.1007\/s13311-021-01108-4_bib76","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1093\/brain\/awg235","article-title":"Immunoglobulins inhibit pathophysiological effects of anti-GQ1b-positive sera at motor nerve terminals through inhibition of antibody binding","volume":"126","author":"Jacobs","year":"2003","journal-title":"Brain"},{"key":"10.1007\/s13311-021-01108-4_bib77","doi-asserted-by":"crossref","unstructured":"Renaud S, Hays AP, Brannagan TH 3rd et al (2005). Gene expression profiling in chronic inflammatory demyelinating polyneuropathy .J Neuroimmunol 159(1\u20132):203\u201314.","DOI":"10.1016\/j.jneuroim.2004.10.021"},{"key":"10.1007\/s13311-021-01108-4_bib78","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1093\/brain\/awh518","article-title":"Gene expression profile in the muscles of patients with inflammatory myopathies: effect of therapy with IVIg and biologic validation of clinical relevant genes","volume":"128","author":"Raju","year":"2005","journal-title":"Brain"},{"key":"10.1007\/s13311-021-01108-4_bib79","doi-asserted-by":"crossref","unstructured":"Leonhard SE,. Mandarakas MR, Gondim FA et al Diagnosis and management of Guillain\u2013Barr\u00e9 syndrome in ten steps Nature Rev Neurol 2019: 15: 671\u201382","DOI":"10.1038\/s41582-019-0250-9"},{"key":"10.1007\/s13311-021-01108-4_bib80","doi-asserted-by":"crossref","unstructured":"Dalakas MC. Guillain-Barr\u00e9 syndrome: The first documented COVID-19\u2013triggered autoimmune neurologic disease: More to come with myositis in the offing Neurol Neuroimmunol Neuroinflammation 2020:7 (5)","DOI":"10.1212\/NXI.0000000000000781"},{"key":"10.1007\/s13311-021-01108-4_bib81","doi-asserted-by":"crossref","unstructured":"Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barre syndrome. Plasma Exchange\/Sandoglobulin Guillain-Barre Syndrome Trial Group. Lancet349, 225\u2013230 (1997).","DOI":"10.1016\/S0140-6736(96)09095-2"},{"key":"10.1007\/s13311-021-01108-4_bib82","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1002\/ana.21737","article-title":"Pharmacokinetics of intravenous immunoglobulin and outcome in Guillain-Barre syndrome","volume":"66","author":"Kuitwaard","year":"2009","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-021-01108-4_bib83","doi-asserted-by":"crossref","unstructured":"Verboon C, Van den Berg B, Cornblath DR et al Second IVIg course in Guillain-Barr. syndrome with poor prognosis: the non-randomised ISID study J Neurol Neurosurg Psychiatry2019; https:\/\/doi.org\/10.1136\/jnnp-2019- 321496","DOI":"10.1136\/jnnp-2019-321496"},{"key":"10.1007\/s13311-021-01108-4_bib84","doi-asserted-by":"crossref","unstructured":"Walgard C, Jacobs BC, Lingsma HF et al Second intravenous immunoglobulin dose in patients with Guillain-Barr\u00e9 syndrome with poor prognosis (SID-GBS): a double-blind, randomised, placebo-controlled trial Lancet Neurol 2021 Apr;20(4):275\u2013283.\u00a0https:\/\/doi.org\/10.1016\/S1474-4422(20)30494-4.","DOI":"10.1016\/S1474-4422(20)30494-4"},{"key":"10.1007\/s13311-021-01108-4_bib85","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/nrneurol.2011.121","article-title":"Advances in the diagnosis, pathogenesis and treatment of CIDP","volume":"7","author":"Dalakas","year":"2011","journal-title":"Nat Rev Neurol"},{"key":"10.1007\/s13311-021-01108-4_bib86","doi-asserted-by":"crossref","unstructured":"Bunschoten C, Jacobs BC Van den Bergh P et al Progress in diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy Lancet Neurol 2019 May 7, 2019","DOI":"10.1016\/S1474-4422(19)30144-9"},{"key":"10.1007\/s13311-021-01108-4_bib87","first-page":"143","article-title":"Dalakas MC Autoimmune antigenic targets at the node of Ranvier in demyelinating disorders Nature","volume":"11","author":"Stathopoulos","year":"2015","journal-title":"Rev Neurol"},{"key":"10.1007\/s13311-021-01108-4_bib88","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/S1474-4422(07)70329-0","article-title":"Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial","volume":"7","author":"Hughes","year":"2008","journal-title":"Lancet Neurol"},{"key":"10.1007\/s13311-021-01108-4_bib89","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1212\/WNL.0b013e3181a0fd80","article-title":"Health-related quality-of-life improvements in CIDP with immune globulin IV 10%: the ICE Study","volume":"72","author":"Merkies","year":"2009","journal-title":"Neurology"},{"key":"10.1007\/s13311-021-01108-4_bib90","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/mus.21236","article-title":"Electrophysiology in chronic inflammatory demyelinating polyneuropathy with IGIV","volume":"39","author":"Bril","year":"2009","journal-title":"Muscle Nerve"},{"key":"10.1007\/s13311-021-01108-4_bib91","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1001\/archneurol.2010.105","article-title":"Timing and course of clinical response to intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy","volume":"67","author":"Latov","year":"2010","journal-title":"Arch Neurol"},{"key":"10.1007\/s13311-021-01108-4_bib92","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1136\/jnnp.56.1.36","article-title":"Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy: a double blind, placebo controlled study","volume":"56","author":"Vermeulen","year":"1993","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1007\/s13311-021-01108-4_bib93","doi-asserted-by":"crossref","unstructured":"Kuitwaaard K, Fokknik W-J, Brusse E et al Maintenance IV immunoglobulin treatment in chronic inflammatory demyelinating polyradiculoneuropathy J Peripher Nerv Syst 2017 Dec;22(4):425\u2013432.\u00a0https:\/\/doi.org\/10.1111\/jns.12242.","DOI":"10.1111\/jns.12242"},{"key":"10.1007\/s13311-021-01108-4_bib94","doi-asserted-by":"crossref","unstructured":"Lewis RA, Cornblath DR Hartung H-P et al Placebo effect in chronic inflammatory demyelinating polyneuropathy: The PATH study and a systematic review J Peripher Nerv Syst. 2020;25:230\u2013237.","DOI":"10.1111\/jns.12402"},{"key":"10.1007\/s13311-021-01108-4_bib95","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1136\/jnnp-2012-304670","article-title":"Serum IgG levels in IV immunoglobulin treated chronic inflammatory demyelinating polyneuropathy","volume":"84","author":"Kuitwaard","year":"2013","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1007\/s13311-021-01108-4_bib96","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/j.1529-8027.2006.00105.x","article-title":"Dose of intravenous immunoglobulins in chronicinflammatory demyelinating polyneuropathy","volume":"11","author":"Rajabally","year":"2006","journal-title":"J Peripher Nerv Syst"},{"key":"10.1007\/s13311-021-01108-4_bib97","doi-asserted-by":"crossref","unstructured":"van Schaik I, Bril V, van Geloven N et al the Path Study group. (2017). Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial Lancet Neurology 2018","DOI":"10.1016\/j.jns.2017.08.225"},{"key":"10.1007\/s13311-021-01108-4_bib98","first-page":"286","volume":"28","author":"Kuitwaard","year":"2021","journal-title":"C Randomized trial of intravenous immunoglobulin maintenance treatment regimens in chronic inflammatory demyelinating polyradiculoneuropathy European Journal of Neurology"},{"issue":"8","key":"10.1007\/s13311-021-01108-4_bib99","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S1474-4422(18)30202-3","article-title":"Oral Fingolimod for Chronic Inflammatory Demyelinating Polyradiculoneuropathy (FORCIDP Trial): A double-blind multicentre, randomised Controlled Trial","volume":"17","author":"Hughes","year":"2018","journal-title":"Lancet Neurol"},{"key":"10.1007\/s13311-021-01108-4_bib100","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1212\/WNL.55.9.1256","article-title":"Multifocal motor neuropathy improved by IVIg: randomized, double-blind, placebo-controlled study","volume":"55","author":"Federico","year":"2000","journal-title":"Neurology"},{"key":"10.1007\/s13311-021-01108-4_bib101","doi-asserted-by":"crossref","unstructured":"Hahn AF, Beydoun SR Lawson V et al A controlled trial of IVIG in multifocal motor neuropathy J Periph Nervous System 2013: 18;321\u2013330","DOI":"10.1111\/jns5.12046"},{"key":"10.1007\/s13311-021-01108-4_bib102","doi-asserted-by":"crossref","unstructured":"Leger JM, Viala K, Cancalon F, et al J Neurol Neurosurg Psychiatry 2008;79:93","DOI":"10.1136\/jnnp.2007.121756"},{"issue":"7","key":"10.1007\/s13311-021-01108-4_bib103","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1212\/01.WNL.0000140497.85952.FA","article-title":"Multifocal motor neuropathy: decrease in conduction blocks and reinnervation with long-term IVIg","volume":"63","author":"Vucic","year":"2004","journal-title":"Neurology."},{"key":"10.1007\/s13311-021-01108-4_bib104","doi-asserted-by":"crossref","unstructured":"Phillips, W.D. & A. Vincent. 2016. Pathogenesis of myasthenia gravis: update on disease types, models, and mechanisms. F1000Res. 5: 1513","DOI":"10.12688\/f1000research.8206.1"},{"key":"10.1007\/s13311-021-01108-4_bib105","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1007\/s13311-015-0398-y","article-title":"Soni M Meriggioli MN Current Treatment, Emerging Translational Therapies, and New Therapeutic Targets for Autoimmune Myasthenia Gravis","volume":"13","author":"Guptil","year":"2016","journal-title":"Neurotherapeutics"},{"key":"10.1007\/s13311-021-01108-4_bib106","doi-asserted-by":"crossref","unstructured":"Dalakas MC Immunotherapy in myasthenia gravis in the era of biologics Nature Rev Neurol 2018: Dec 20.\u00a0https:\/\/doi.org\/10.1038\/s41582-018-0110-z","DOI":"10.1038\/s41582-018-0110-z"},{"key":"10.1007\/s13311-021-01108-4_bib107","doi-asserted-by":"crossref","unstructured":"Gajdos, P., Chevret, S., Clair, B., Tranchant, C. & Chastang, C. Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Myasthenia Gravis Clinical Study Group. Ann Neurol41, 789\u2013796, https:\/\/doi.org\/10.1002\/ana.410410615 (1997).","DOI":"10.1002\/ana.410410615"},{"key":"10.1007\/s13311-021-01108-4_bib108","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1001\/archneur.62.11.1689","article-title":"Treatment of myasthenia gravis exacerbation with intravenous immunoglobulin: a randomized double-blind clinical trial","volume":"62","author":"Gajdos","year":"2005","journal-title":"Arch Neurol"},{"key":"10.1007\/s13311-021-01108-4_bib109","doi-asserted-by":"crossref","unstructured":"Gajdos, P., Chevret, S. & Toyka, K. V. Intravenous immunoglobulin for myasthenia gravis. Cochrane Database Syst Rev12, CD002277,\u00a0https:\/\/doi.org\/10.1002\/14651858.CD002277.pub4 (2012).","DOI":"10.1002\/14651858.CD002277.pub4"},{"key":"10.1007\/s13311-021-01108-4_bib110","doi-asserted-by":"crossref","unstructured":"Karelis G Balasa R, De Bleeker JL et al A Phase 3 Multicenter, Prospective, Open-Label Efficacy and Safety Study of Immune Globulin (Human) 10% Caprylate\/Chromatography Purified in Patients with Myasthenia Gravis Exacerbations Eur Neurol 2019;81:223\u2013230\u00a0https:\/\/doi.org\/10.1159\/000502818","DOI":"10.1159\/000502818"},{"key":"10.1007\/s13311-021-01108-4_bib111","doi-asserted-by":"crossref","unstructured":"Beecher G Anderson D Siddiqi Z et al Subcutaneous immunoglobulin in myasthenia gravis exacerbation A prospective, open-label trial Neurology\u00ae 2017;89:1\u20137","DOI":"10.1212\/WNL.0000000000004365"},{"key":"10.1007\/s13311-021-01108-4_bib112","doi-asserted-by":"crossref","unstructured":"Hellmann MA, Mosberg-Galili R, Lotan I, Steiner I Maintianance IVIg therapy in myasthenia gravis does not affect disease activity. J Neurol. Sciences 2014","DOI":"10.1016\/j.jns.2013.10.043"},{"key":"10.1007\/s13311-021-01108-4_bib113","doi-asserted-by":"crossref","unstructured":"Dalakas MC. IVIg in the chronic management of myasthenia gravis: is it enough for your money? J Neurol. Sciences (Editorial) 2014.","DOI":"10.1016\/j.jns.2013.12.034"},{"key":"10.1007\/s13311-021-01108-4_bib114","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1056\/NEJMra1402225","article-title":"Inflammatory Myopathies N","volume":"372","author":"Dalakas","year":"2015","journal-title":"Engl J. Med"},{"key":"10.1007\/s13311-021-01108-4_bib115","doi-asserted-by":"crossref","unstructured":"Aggrarwal R, Charles-Shoeman C Schessl et al Prospective, double-blind, randomized, placebocontrolled phase III study evaluating efficacy and safety of octagam 10% in patients with dermatomyositis (\u201cProDERM Study\u201d) Medicine (2021) 100:1","DOI":"10.1097\/MD.0000000000023677"},{"key":"10.1007\/s13311-021-01108-4_bib116","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1212\/WNL.48.3.712","article-title":"Treatment of inclusion-body myositis with IVIg: a double-blind, placebo-controlled study","volume":"48","author":"Dalakas","year":"1997","journal-title":"Neurology"},{"key":"10.1007\/s13311-021-01108-4_bib117","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1152\/physrev.00010.2016","article-title":"Autoantibodies to Synaptic Receptors and Neuronal Cell Surface Proteins in Autoimmune Diseases of the Central Nervous System","volume":"97","author":"Dalmau","year":"2017","journal-title":"Physiological reviews"},{"key":"10.1007\/s13311-021-01108-4_bib118","doi-asserted-by":"crossref","unstructured":"Alexopoulos H, Dalakas MC. The immunobiology of autoimmune encephalitides. J Autoimmun. 2019 Nov;104:102339. https:\/\/doi.org\/10.1016\/j.jaut.2019.102339. Epub 2019 Oct 11. PMID: 31611142","DOI":"10.1016\/j.jaut.2019.102339"},{"key":"10.1007\/s13311-021-01108-4_bib119","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/ana.25655","article-title":"Randomized placebo-controlled trial of intravenous immunoglobulin in autoimmune LGI1\/CASPR2 epilepsy","volume":"87","author":"Dubey","year":"2020","journal-title":"Ann Neurol."},{"key":"10.1007\/s13311-021-01108-4_bib120","doi-asserted-by":"crossref","unstructured":"Manganotti P, Furlanisi G, Ajcevic M et al Intravenous immunoglobulin response in new\u2011onset refractory status epilepticus (NORSE) COVID\u201119 adult patients Journal of Neurology https:\/\/doi.org\/10.1007\/s00415-021-10468-y","DOI":"10.1007\/s00415-021-10468-y"},{"key":"10.1007\/s13311-021-01108-4_bib121","doi-asserted-by":"crossref","unstructured":"Chen JJ, Flanagan EP, Bhatti MT et al Steroid-sparing maintenance immunotherapy forMOG-IgG associated disorder Neurology\u00ae 2020;95:e111-e120.\u00a0https:\/\/doi.org\/10.1212\/WNL.0000000000009758","DOI":"10.1212\/WNL.0000000000009758"},{"key":"10.1007\/s13311-021-01108-4_bib122","doi-asserted-by":"crossref","unstructured":"lin Jie , Xue B, Zue R et al 2021 Intravenous Immunoglobulin as the rescue treatment in NMOSD patients Neurol Sci 2021","DOI":"10.1007\/s10072-021-05079-4"},{"key":"10.1007\/s13311-021-01108-4_bib123","doi-asserted-by":"crossref","unstructured":"Lim YM et al et al Beneficial effects of intravenous immunoglobulin as an add-on therapy to azathioprine for NMO-IgG-seropositive neuromyelitis optica spectrum disorders Mult Sclerosis .\u00a02020 Jul;42:102109.\u00a0https:\/\/doi.org\/10.1016\/j.msard.2020.102109.Epub 2020 Apr 28","DOI":"10.1016\/j.msard.2020.102109"},{"key":"10.1007\/s13311-021-01108-4_bib124","doi-asserted-by":"crossref","unstructured":"Whittman DH et al Treatment of MOG antibody associated disorders: results of an international survey J Neuro 2020 Dec;267(12):3565\u20133577.\u00a0https:\/\/doi.org\/10.1007\/s00415-020-10026-y.\u00a0Epub 2020 Jul 4.","DOI":"10.1007\/s00415-020-10026-y"},{"key":"10.1007\/s13311-021-01108-4_bib125","doi-asserted-by":"crossref","unstructured":"Oaklander AL, Nolano M. Scientific Advances in and Clinical Approaches to Small-Fiber Polyneuropathy: A Review. JAMA Neurol 2019,","DOI":"10.1001\/jamaneurol.2019.2917"},{"key":"10.1007\/s13311-021-01108-4_bib126","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1097\/WCO.0000000000000472","article-title":"Small fibre neuropathy","volume":"30","author":"Cazzato","year":"2017","journal-title":"Curr Opin Neurol"},{"key":"10.1007\/s13311-021-01108-4_bib127","doi-asserted-by":"crossref","unstructured":"Pavlakis P, Alexopoulos H, Kosmidis ML et al Peripheral neuropathies in Sjogren syndrome: a new reappraisal. J Neurol Neurosurg Psychiatry Published on line Dec. 16 2010,https:\/\/doi.org\/10.1136\/jnnp.2010.22210.","DOI":"10.1136\/jnnp.2010.222109"},{"key":"10.1007\/s13311-021-01108-4_bib128","doi-asserted-by":"crossref","unstructured":"Liu X, Treister R, Lang M, Oaklander AL. IVIg for apparently autoimmune small-fiber polyneuropathy: first analysis of efficacy and safety. Ther Adv Neurol Disord. 2018 Jan 8;11 https:\/\/doi.org\/10.1177\/1756285617744484. 1756285617744484.","DOI":"10.1177\/1756285617744484"},{"key":"10.1007\/s13311-021-01108-4_bib129","doi-asserted-by":"crossref","unstructured":"Tholance Y, Moritz CP, Rosier C, et al. Clinical characterisation of sensory neuropathy with anti-FGFR3 autoantibodies: the anti-FGFR3 antibody Study Group. J Neurol Neurosurg Psychiatry. 2020 Jan;91(1):49\u201357.\u00a0https:\/\/doi.org\/10.1136\/jnnp-2019-321849. Epub 2019 Nov 5. PMID. 31690697","DOI":"10.1136\/jnnp-2019-321849"},{"key":"10.1007\/s13311-021-01108-4_bib130","doi-asserted-by":"crossref","unstructured":"Geerts M. de Greef B TA, Sopacua M et al Intravenous Immunoglobulin Therapy inPatients With Painful Idiopathic Small Fiber Neuropathy Neurology 2021;96:e2534-e2545. https:\/\/doi.org\/10.1212\/WNL.0000000000011919","DOI":"10.1212\/WNL.0000000000011919"},{"key":"10.1007\/s13311-021-01108-4_bib131","doi-asserted-by":"crossref","unstructured":"Goebel, A. et al. Intravenous immunoglobulin treatment of the complex regional pain syndrome: a randomized trial. Ann Intern Med 152, 152\u2013158,\u00a0https:\/\/doi.org\/10.1059\/0003-4819-152-3-201002020-00006 (2010)","DOI":"10.7326\/0003-4819-152-3-201002020-00006"},{"key":"10.1007\/s13311-021-01108-4_bib132","doi-asserted-by":"crossref","unstructured":"Xu M. Bennett D LH, Querol LA et al Pain and the immune system: emerging concepts of IgG-mediated autoimmune pain and Immunotherapies J Neurol Neurosurg Psychiatry 2018;\u00a0https:\/\/doi.org\/10.1136\/jnnp-2018- 318556","DOI":"10.1136\/jnnp-2018-318556"},{"key":"10.1007\/s13311-021-01108-4_bib133","doi-asserted-by":"crossref","unstructured":"Dalakas MC, Elder G, Hallett M, et al A Long term follow-up study of patients with postpoliomyelitis neuromuscular symptoms. N Engl J Med 314:959\u201363; 1986.","DOI":"10.1056\/NEJM198604103141505"},{"key":"10.1007\/s13311-021-01108-4_bib134","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/j.1749-6632.1995.tb27543.x","article-title":"Pathogenetic mechanisms of post-polio syndrome: morphological, electrophysiological, virological, and immunological correlations","volume":"753","author":"Dalakas","year":"1995","journal-title":"Ann N Y Acad Sci"},{"key":"10.1007\/s13311-021-01108-4_bib135","doi-asserted-by":"crossref","unstructured":"Gonzalez, H. et al. Intravenous immunoglobulin for post-polio syndrome: a randomised controlled trial. Lancet Neurol5, 493\u2013500,\u00a0https:\/\/doi.org\/10.1016\/S1474-4422(06)70447-1 (2006)","DOI":"10.1016\/S1474-4422(06)70447-1"},{"key":"10.1007\/s13311-021-01108-4_bib136","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1212\/WNL.40.2.212","article-title":"High dose intravenous immunoglobulin in the treatment of demyelinating neuropathy associated with monoclonal gammopathy","volume":"40","author":"Cook","year":"1990","journal-title":"Neurology"},{"key":"10.1007\/s13311-021-01108-4_bib137","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1002\/ana.410400516","article-title":"A controlled study of intravenous immunoglobulin in demyelinating neuropathy with IgM gammopathy","volume":"40","author":"Dalakas","year":"1996","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-021-01108-4_bib138","doi-asserted-by":"crossref","unstructured":"Weiss MD, Dalakas MC, Lauter CJ, et al Variability in the Binding of Anti-MAG and Anti-SGPG Antibodies to Target Antigens in Demyelinating Neuropathy and IgM Paraproteinemia. J Neuroimmunol 95:174\u2013184, 1999.","DOI":"10.1016\/S0165-5728(98)00247-1"},{"key":"10.1007\/s13311-021-01108-4_bib139","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1136\/jnnp.2003.033399","article-title":"Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease","volume":"75","author":"Dodel","year":"2004","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1007\/s13311-021-01108-4_bib140","unstructured":"Relkin NR Thomas RG Rissman RA et al A phase 3 trial of IV immunoglobulin for Alzheimer disease Neurology 2017; 88:1\u20138"},{"key":"10.1007\/s13311-021-01108-4_bib141","doi-asserted-by":"crossref","unstructured":"Dalakas MC, Stein DP, Otero C, et al. Effect of high-dose intravenous immunoglobulin on amyotrophic lateral sclerosis and multifocal motor neuropathy. Arch Neuro. 1994;l 51, 861\u2013864.","DOI":"10.1001\/archneur.1994.00540210031010"},{"key":"10.1007\/s13311-021-01108-4_bib142","doi-asserted-by":"crossref","unstructured":"Plazzi, G. et al. Intravenous high-dose immunoglobulin treatment in recent onset childhood narcolepsy with cataplexy. J Neurol 255, 1549\u20131554, https:\/\/doi.org\/10.1007\/s00415-008-0983-7 (2008). yes","DOI":"10.1007\/s00415-008-0983-7"},{"issue":"3","key":"10.1007\/s13311-021-01108-4_bib143","first-page":"441","article-title":"Intravenous Immunoglobulin Therapy in Pediatric Narcolepsy: A Nonrandomized","volume":"13","author":"Lecendreux","year":"2017","journal-title":"Open-Label, Controlled, Longitudinal Observational Study J Clin Sleep Med"},{"key":"10.1007\/s13311-021-01108-4_bib144","unstructured":"Dalakas MC: IgG4-mediated neurological autoimmunities: Understanding pathogenicity of IgG4, ineffectiveness of IVIg and long-lasting benefits of anti-B cell therapies Neurolol Neuroimmunol Neuroinflammation In press"},{"key":"10.1007\/s13311-021-01108-4_bib145","doi-asserted-by":"crossref","unstructured":"Fokkink WJ, Haarman AE and Tio-Gillen AP, et al. Neonatal Fc receptor promoter genepolymorphism does not predict pharmacokinetics of IVIg or the clinical course of GBS. Ann ClinTransl Neurol 2016; 3: 547\u2013551. Journal Article.\u00a0https:\/\/doi.org\/10.1002\/acn3.","DOI":"10.1002\/acn3.307"},{"key":"10.1007\/s13311-021-01108-4_bib146","doi-asserted-by":"crossref","unstructured":"Kapoor M, Reilly MM, Manji H et al Dramatic clinical response to ultra-high dose IVIg in otherwise treatment resistant inflammatory neuropathies International Journal of Neuroscience,\u00a0https:\/\/doi.org\/10.1080\/00207454.2020.1815733","DOI":"10.1080\/00207454.2020.1815733"},{"key":"10.1007\/s13311-021-01108-4_bib147","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2217\/imt.13.146","article-title":"Subcutaneous IgG in neurologic diseases","volume":"6","author":"Berger","year":"2014","journal-title":"Immunotherapy"},{"key":"10.1007\/s13311-021-01108-4_bib148","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1136\/jnnp-2013-305644","article-title":"current evidence base and future prospects","volume":"85","author":"Rajabally","year":"2014","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1007\/s13311-021-01108-4_bib149","doi-asserted-by":"crossref","unstructured":"Markvardsen LH, Harbo T. Subcutaneous immunoglobulin treatment in CIDP and MMN. Efficacy, treatment satisfaction and costs. 2017; J Neurol Sci 378:19\u201325.","DOI":"10.1016\/j.jns.2017.04.039"},{"key":"10.1007\/s13311-021-01108-4_bib150","doi-asserted-by":"crossref","unstructured":"Dalakas MC Subcutaneous IgG for Chronic Inflammatory Demyelinating Polyneuropathy. Lancet Neurol 17 (1):20\u201321, 2018","DOI":"10.1016\/S1474-4422(17)30379-4"},{"issue":"6","key":"10.1007\/s13311-021-01108-4_bib151","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1056\/NEJMra1907805","article-title":"Placebo and Nocebo effects","volume":"382","author":"Colloca","year":"2020","journal-title":"N Engl J Med."},{"key":"10.1007\/s13311-021-01108-4_bib152","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1002\/ana.21577","article-title":"Placebo-Controlled trial of Rituximab in IgM anti-Myelin Associated Glycoprotein antibody demyelinating neuropathy","volume":"65","author":"Dalakas","year":"2009","journal-title":"Ann Neurol."},{"key":"10.1007\/s13311-021-01108-4_bib153","doi-asserted-by":"crossref","unstructured":"Kim D, Kung CS, Perez DL. Helping the Public Understand Adverse Events Associated With COVID-19 Vaccinations: Lessons Learned From Functional Neurological Disorder JAMA Neurol 2021 Apr 9.\u00a0https:\/\/doi.org\/10.1001\/jamaneurol.2021.1042.\u00a0Online ahead of print.","DOI":"10.1001\/jamaneurol.2021.1042"},{"key":"10.1007\/s13311-021-01108-4_bib154","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jns.2018.11.031","article-title":"Current practice patterns in CIDP: A cross-sectional survey of neurologists in the United States","volume":"397","author":"Gelinas","year":"2019","journal-title":"Journal of the Neurological Sciences"},{"key":"10.1007\/s13311-021-01108-4_bib155","doi-asserted-by":"crossref","unstructured":"Dalakas MC. Controlled studies with high-dose intravenous immunoglobulin in the treatment of dermatomyositis, inclusion body myositis, and polymyositis. Neurology. 1998 Dec;51(6 Suppl 5):S37-45. https:\/\/doi.org\/10.1212\/wnl.51.6_suppl_5.s37. PMID: 9851729","DOI":"10.1212\/WNL.51.6_Suppl_5.S37"},{"key":"10.1007\/s13311-021-01108-4_bib156","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/ncpneuro0376","article-title":"Drug Insight: the use of intravenous immunoglobulin in neurology\u2013therapeutic considerations and practical issues","volume":"3","author":"Gold","year":"2007","journal-title":"Nat Clin Pract Neurol"},{"key":"10.1007\/s13311-021-01108-4_bib157","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/jns.12267","article-title":"A randomised, multi-centre phase III study of 3 different doses of intravenous immunoglobulin 10% in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ProCID trial): study design and protocol","volume":"23","author":"Cornblath","year":"2018","journal-title":"J Peripher Nerv Syst"},{"key":"10.1007\/s13311-021-01108-4_bib158","unstructured":"Cornblath DR, Hartung HP, Katzberg HD, et al Lancet Neurology In press"},{"issue":"13","key":"10.1007\/s13311-021-01108-4_bib159","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1212\/WNL.0b013e31824de293","article-title":"Evidence-based guideline: Intravenous immunoglobulin in the treatment of neuromuscular disorders","volume":"78","author":"Patwa","year":"2012","journal-title":"Neurology"},{"key":"10.1007\/s13311-021-01108-4_bib160","doi-asserted-by":"crossref","first-page":"316","DOI":"10.7326\/0003-4819-122-4-199502150-00021","article-title":"Aseptic meningitis and intravenous immunoglobulin","volume":"122","author":"Dalakas","year":"1995","journal-title":"Ann Intern Med."},{"key":"10.1007\/s13311-021-01108-4_bib161","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.7326\/0003-4819-127-12-199712150-00022","article-title":"Meningitis and skin reactions after Intravenous Immunoglobulin therapy","volume":"127","author":"Dalakas","year":"1997","journal-title":"Ann Intern Med."},{"key":"10.1007\/s13311-021-01108-4_bib162","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/BF00915419","article-title":"Immunoglobulin prophylaxis in patients with antibody deficiency syndromes and anti-IgA antibodies","volume":"7","author":"Bjorkander","year":"1987","journal-title":"J Clin Immunol"},{"key":"10.1007\/s13311-021-01108-4_bib163","doi-asserted-by":"crossref","unstructured":"Burks, A. W., Sampson, H. A. & Buckley, R. H. Anaphylactic reactions after gamma globulin administration in patients with hypogammaglobulinemia. Detection of IgE antibodies to IgA. N Engl J Med314, 560\u2013564,\u00a0https:\/\/doi.org\/10.1056\/NEJM198602273140907 (1986).","DOI":"10.1056\/NEJM198602273140907"},{"key":"10.1007\/s13311-021-01108-4_bib164","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0140-6736(86)92511-0","article-title":"Fatal thrombotic events during treatment of autoimmune thrombocytopenia with intravenous immunoglobulin in elderly patients","volume":"2","author":"Woodruff","year":"1986","journal-title":"Lancet"},{"key":"10.1007\/s13311-021-01108-4_bib165","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/BF02076702","article-title":"Hyperviscosity in HIV infected children\u2013a potential hazard during intravenous immunoglobulin therapy","volume":"61","author":"Hague","year":"1990","journal-title":"Blut"},{"key":"10.1007\/s13311-021-01108-4_bib166","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1212\/WNL.44.2.223","article-title":"High-dose intravenous immunoglobulin and serum viscosity: risk of precipitating thromboembolic events","volume":"44","author":"Dalakas","year":"1994","journal-title":"Neurology"},{"key":"10.1007\/s13311-021-01108-4_bib167","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1212\/01.WNL.0000074394.15882.83","article-title":"Strokes, thromboembolic events, and IVIg: rare incidents blemish an excellent safety record","volume":"60","author":"Dalakas","year":"2003","journal-title":"Neurology"},{"key":"10.1007\/s13311-021-01108-4_bib168","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1056\/NEJM199210013271416","article-title":"High-dose intravenous immune globulin and acute renal failure","volume":"327","author":"Ellie","year":"1992","journal-title":"N Engl J Med."},{"key":"10.1007\/s13311-021-01108-4_bib169","first-page":"157","article-title":"Intravenous immunoglobulin induced-nephropathy: a complication of IVIg therapy","volume":"11","author":"Ahsan","year":"1998","journal-title":"J Nephrol."},{"key":"10.1007\/s13311-021-01108-4_bib170","doi-asserted-by":"crossref","unstructured":"Zsch\u00fcntzsch J, Voss J, Creus K et al Provision of an explanation for the inefficacy of immunotherapy in sIBM: quantitative assessment of inflammation and \u03b2-amyloid in the muscle Arthritis Rheum. 2012; 64(12): 4094\u2013103.","DOI":"10.1002\/art.37692"},{"key":"10.1007\/s13311-021-01108-4_bib171","doi-asserted-by":"crossref","unstructured":"Dalakas MC Progress in the Therapy of Myasthenia Gravis: Getting closer to effective targeted Immunotherapies Curr Opin Neurol 2020, 33:545\u2013552","DOI":"10.1097\/WCO.0000000000000858"},{"issue":"Suppl 1","key":"10.1007\/s13311-021-01108-4_bib172","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/s10875-014-0024-5","article-title":"Mechanistic effects of IVIg in Neuroinflammatory Diseases: Conclusions based on clinicopathologic correlations","volume":"34","author":"Dalakas","year":"2014","journal-title":"J Clinical Immunology"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-021-01108-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13311-021-01108-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923007109?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923007109?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-021-01108-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T06:57:41Z","timestamp":1761807461000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747923007109"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":172,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S1878747923007109"],"URL":"https:\/\/doi.org\/10.1007\/s13311-021-01108-4","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Update on Intravenous Immunoglobulin in Neurology: Modulating Neuro-autoimmunity, Evolving Factors on Efficacy and Dosing and Challenges on Stopping Chronic IVIg Therapy","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s13311-021-01108-4","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2021 The authors. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}